Exelixis Inc (EXEL)
34.83
+0.18
(+0.52%)
USD |
NASDAQ |
Nov 21, 16:00
34.82
0.00 (0.00%)
After-Hours: 20:00
Exelixis Enterprise Value: 8.758B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 8.758B |
| November 20, 2024 | 8.706B |
| November 19, 2024 | 8.638B |
| November 18, 2024 | 8.669B |
| November 15, 2024 | 8.649B |
| November 14, 2024 | 8.820B |
| November 13, 2024 | 8.860B |
| November 12, 2024 | 9.049B |
| November 11, 2024 | 9.146B |
| November 08, 2024 | 9.163B |
| November 07, 2024 | 9.035B |
| November 06, 2024 | 8.952B |
| November 05, 2024 | 8.740B |
| November 04, 2024 | 8.603B |
| November 01, 2024 | 8.555B |
| October 31, 2024 | 8.292B |
| October 30, 2024 | 8.075B |
| October 29, 2024 | 7.016B |
| October 28, 2024 | 6.950B |
| October 25, 2024 | 6.770B |
| October 24, 2024 | 6.838B |
| October 23, 2024 | 6.898B |
| October 22, 2024 | 7.044B |
| October 21, 2024 | 6.996B |
| October 18, 2024 | 7.070B |
| Date | Value |
|---|---|
| October 17, 2024 | 7.116B |
| October 16, 2024 | 7.198B |
| October 15, 2024 | 6.956B |
| October 14, 2024 | 6.310B |
| October 11, 2024 | 6.307B |
| October 10, 2024 | 6.158B |
| October 09, 2024 | 6.078B |
| October 08, 2024 | 6.067B |
| October 07, 2024 | 6.330B |
| October 04, 2024 | 6.430B |
| October 03, 2024 | 6.310B |
| October 02, 2024 | 6.384B |
| October 01, 2024 | 6.327B |
| September 30, 2024 | 6.227B |
| September 27, 2024 | 6.403B |
| September 26, 2024 | 6.483B |
| September 25, 2024 | 6.432B |
| September 24, 2024 | 6.494B |
| September 23, 2024 | 6.517B |
| September 20, 2024 | 6.534B |
| September 19, 2024 | 6.651B |
| September 18, 2024 | 6.648B |
| September 17, 2024 | 6.871B |
| September 16, 2024 | 6.834B |
| September 13, 2024 | 6.546B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
3.278B
Minimum
Oct 10 2022
9.163B
Maximum
Nov 08 2024
5.278B
Average
5.317B
Median
Jun 18 2024
Enterprise Value Benchmarks
| Merck & Co Inc | 276.21B |
| ADMA Biologics Inc | 5.050B |
| Vericel Corp | 2.697B |
| Catalyst Pharmaceuticals Inc | 2.077B |
| Inovio Pharmaceuticals Inc | 21.16M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 117.97M |
| Revenue (Quarterly) | 539.54M |
| Total Expenses (Quarterly) | 351.70M |
| EPS Diluted (Quarterly) | 0.40 |
| Gross Profit Margin (Quarterly) | 96.79% |
| Profit Margin (Quarterly) | 21.87% |
| Earnings Yield | 4.48% |
| Operating Earnings Yield | 5.80% |
| Normalized Earnings Yield | 5.105 |